Johnson & Johnson $JNJ Shares Sold by Redwood Park Advisors LLC

Redwood Park Advisors LLC cut its holdings in Johnson & Johnson (NYSE:JNJ) by 56.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 738 shares of the company’s stock after selling 939 shares during the period. Redwood Park Advisors LLC’s holdings in Johnson & Johnson were worth $113,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Brighton Jones LLC boosted its position in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares during the period. Wealth Group Ltd. acquired a new position in shares of Johnson & Johnson during the first quarter valued at $218,000. Jaffetilchin Investment Partners LLC boosted its holdings in shares of Johnson & Johnson by 1.9% during the first quarter. Jaffetilchin Investment Partners LLC now owns 36,300 shares of the company’s stock valued at $6,020,000 after acquiring an additional 685 shares during the period. Philip James Wealth Mangement LLC boosted its holdings in shares of Johnson & Johnson by 1.7% during the first quarter. Philip James Wealth Mangement LLC now owns 77,415 shares of the company’s stock valued at $12,839,000 after acquiring an additional 1,257 shares during the period. Finally, Achmea Investment Management B.V. boosted its stake in Johnson & Johnson by 15.7% during the 1st quarter. Achmea Investment Management B.V. now owns 248,227 shares of the company’s stock valued at $41,166,000 after purchasing an additional 33,641 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of analyst reports. Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. JPMorgan Chase & Co. boosted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. The Goldman Sachs Group boosted their price target on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday, October 9th. Loop Capital set a $190.00 price target on Johnson & Johnson in a research report on Wednesday, October 22nd. Finally, Argus set a $210.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 15th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $199.05.

Johnson & Johnson Trading Down 0.0%

Shares of Johnson & Johnson stock opened at $190.31 on Tuesday. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The firm has a market cap of $458.50 billion, a price-to-earnings ratio of 18.37, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. The business has a fifty day simple moving average of $182.54 and a 200-day simple moving average of $166.65. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.48.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.